P41 - PT-141 - 10 MG - Research Use Only

Name: P41 - PT-141 - 10 MG - Research Use Only
Brand: Peptific
SKU: P41
Price: 18 USD
Availability: OutOfStock

PT-141 (bremelanotide) is an MC3R/MC4R agonist FDA-approved for female HSDD — the only peptide with regulatory approval for sexual function via central melanocortin receptor activation.

Temporarily unavailable

This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.

$18.00

PT-141-

$18.00

✓HPLC purity tested
✓COA per lot, on request
✓Lyophilized, sealed
✓US shipping, tracked

FDA-approved as Vyleesi (2019) for female HSDD — the only completed regulatory approval for central MCR-mediated sexual function
MC3R/MC4R selective — reduced MC1R tanning activity versus Melanotan 2 for cleaner receptor dissection
Central mechanism (hypothalamic MC4R) vs peripheral mechanism — unique pharmacological profile in sexual function research
Phase III RECONNECT data: statistically significant improvements in desire and distress endpoints
Reference compound for MC4R neuropharmacology and hypothalamic sexual arousal circuit research

✓

Free shipping on orders over $150

Research Supplies

Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.

Ask about a research kit →

Need the COA before you order? Request it here.

In your order

What ships when you order PT-141

Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.

The Peptific standard

Why researchers buy from Peptific instead of grey-market vendors

Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.

Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.

How it works

The PT-141 mechanism

PT-141 activates melanocortin receptors (primarily MC3R and MC4R) in hypothalamic circuits, producing central sexual arousal signals without peripheral hormone modulation. Reduced MC1R activity versus Melanotan 2 minimizes tanning effects. Phase III RECONNECT trials demonstrated significant improvement in sexual desire and associated distress in premenopausal women with HSDD.

Compound profile

Class: Cyclic heptapeptide MC3R/MC4R agonist
Selectivity: MC3R > MC4R >> MC1R (reduced tanning vs MT-2)
Molecular weight: ~1,025 Da
Half-life: ~2.7 hours in vivo
CAS: 189691-06-3
Clinical status: FDA-approved (Vyleesi) for female HSDD, 2019
Research category: MC4R neuropharmacology, sexual function, hypothalamic circuits
Storage: Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days

Product definition

What is PT-141?

PT-141 (bremelanotide) is an MC3R/MC4R agonist FDA-approved for female HSDD — the only peptide with regulatory approval for sexual function via central melanocortin receptor activation.

PT-141 (bremelanotide; Palatin Technologies / AMAG Pharmaceuticals) is a cyclic heptapeptide derived from the Melanotan research program that produced the first FDA-approved pharmacological treatment for female HSDD in 2019. Its structure is an α-MSH ring-closed analog: the N-terminal acetyl group of α-MSH is removed, enabling cyclization that reduces MC1R selectivity while preserving MC3R/MC4R engagement. The pharmacological mechanism is distinct from other sexual function treatments: PT-141 acts centrally via hypothalamic MC4R activation, a receptor distribution concentrated in the arcuate nucleus, PVN, and VMH — regions governing sexual motivation, appetite, and autonomic function. This CNS mechanism contrasts with PDE5 inhibitors (peripheral vascular) and testosterone (hormonal). The RECONNECT Phase III program documented this mechanism's clinical utility in premenopausal women, providing a validated model for studying CNS-mediated sexual arousal pharmacology.

Research audience

Who studies PT-141?

PT-141 is used by researchers in MC4R neuropharmacology, hypothalamic circuit biology, central sexual arousal mechanisms, melanocortin receptor selectivity studies, and neuroendocrine pharmacology. It is the pharmacologically validated reference compound for any research addressing MC3R/MC4R-mediated sexual function.

Research context

What does the preclinical literature say about PT-141?

PT-141 emerged from the Melanotan 2 research program when investigators studying MT-2's pigmentation effects in rats observed unexpected sexual behavior effects — erections and lordosis in treated animals — attributable to MC4R activation in hypothalamic circuits. This discovery pivoted Palatin Technologies' research program toward investigating melanocortin receptor agonism as a mechanism for sexual dysfunction treatment. The preclinical to clinical progression documented the MC4R sexual arousal pathway step by step: rodent behavioral studies established the mechanism, Phase II trials in humans confirmed dose-dependent effects on arousal and desire in premenopausal women and erectile function in men (though the male indication was not pursued to approval), and Phase III RECONNECT documented the approved HSDD endpoint. In preclinical research contexts, PT-141 is used to study hypothalamic MC4R biology independent of the sexual function application — the receptor is expressed in circuits governing feeding behavior, energy homeostasis, and autonomic function, making MC4R pharmacology relevant to metabolic neuroscience beyond sexual function research.

Common questions

How does PT-141 differ mechanistically from PDE5 inhibitors like sildenafil?

PDE5 inhibitors (sildenafil, tadalafil) act peripherally — they enhance vascular response to sexual stimulation by preventing cGMP degradation in penile/clitoral tissue. They require sexual stimulation to work and have no central nervous system activity. PT-141 acts centrally via hypothalamic MC4R activation — it generates the CNS sexual arousal signal that drives desire and motivation, independent of peripheral vascular function. The two mechanisms are pharmacologically distinct and potentially complementary in research designs.

Can PT-141 be used in male sexual function research?

Yes — PT-141 has been studied in male erectile function in Phase II trials, where it showed dose-dependent improvements in erection quality. The FDA approval was for female HSDD, but the MC4R mechanism is not sex-specific: the receptor is expressed in both male and female hypothalamic circuits governing sexual motivation. Male sexual function research using PT-141 is an established part of the preclinical and early clinical literature.

What is the storage and stability profile of PT-141?

Lyophilized PT-141 is stable at −20°C. Reconstituted, store at 2–8°C and use within 30 days. The cyclic disulfide bridge is stable under neutral storage conditions but should not be exposed to reducing agents. At approximately 2.7 hours half-life, PT-141 clears relatively quickly — protocols requiring prolonged CNS MCR exposure may need to account for this in dosing design.